Chimeric Hemagglutinin Vaccines for Broad Influenza Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current influenza vaccination strategies struggle to effectively protect against antigenically diverse influenza strains and novel subtypes due to the constant evolution of influenza viruses, making it difficult to predict and prepare for potential pandemics.
Innovation Solution
Development of chimeric influenza hemagglutinin (HA) polypeptides that combine a stable stem domain from one subtype with a globular head domain from another, inducing a cross-protective immune response against conserved HA domains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional influenza vaccines use strain-specific hemagglutinin proteins, then they provide targeted immunity against specific strains, but they fail to protect against antigenically diverse strains and novel subtypes due to constant viral evolution
Solution Approach 1:
The hemagglutinin protein is divided into two functional segments: a conserved stem domain that remains relatively stable across strains and a variable head domain that changes with each strain. By targeting the stem domain specifically, the vaccine achieves broad protection across multiple influenza subtypes while maintaining reliability through conservation of this critical structural region.
Solution Approach 2:
The chimeric hemagglutinin construct serves multiple functions simultaneously: it presents the conserved stem domain for broad cross-strain recognition and includes a stabilized head domain that maintains immunogenicity. This universal design allows a single vaccine formulation to potentially protect against multiple influenza strains, eliminating the need for annual strain-specific vaccines.
2Reliability
If influenza vaccines are updated annually to match circulating strains, then they maintain effectiveness against current strains, but they cannot prepare for novel subtypes and pandemics due to the constant evolution of influenza viruses
Solution Approach 1:
The vaccine design performs preliminary action by pre-targeting the conserved stem domain that will remain stable even as viruses evolve. This preliminary focus on conservation allows the vaccine to maintain effectiveness against circulating strains while simultaneously being prepared for novel subtypes that have not yet emerged, eliminating the need for annual updates.
Solution Approach 2:
The invention changes the targeting parameter from the variable head domain to the conserved stem domain. This parameter change fundamentally alters the vaccine's ability to adapt: instead of tracking viral changes year-to-year, the vaccine locks onto a stable structural parameter that defines the virus family, providing both reliability for current strains and adaptability for future variants.
3Reliability
If the vaccine targets the variable head domain of hemagglutinin, then it provides strain-specific immunity, but it cannot provide cross-protective immunity against conserved domains across different subtypes
Solution Approach 1:
The hemagglutinin is segmented into head and stem domains with distinct functional characteristics. The head domain provides strain-specific recognition while the stem domain provides cross-protective immunity. By designing the vaccine to target the stem domain, the invention achieves cross-protective immunity while maintaining the ability to respond to specific strains through the stabilized head domain component.
Solution Approach 2:
The chimeric hemagglutinin construct is a composite molecule combining elements from different influenza subtypes: a stem domain from one subtype and a head domain from another. This composite design allows the vaccine to present both conserved stem structures for broad protection and stabilized head structures for maintained immunogenicity, achieving both cross-protection and strain-specific response capabilities.
Data Source
AI summary
Provided herein are chimeric influenza hemagglutinin (HA) polypeptides, compositions comprising the same, vaccines comprising the same, and methods of their use.